title: Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry).
abstract: Randomized trials have demonstrated the ability of drug-eluting stents to decrease the risk of restenosis after coronary stent implantation. However, the incidences of major cardiovascular/cerebral adverse events (MACCEs) and target vessel revascularization (TVR) during follow-up in a routine clinical setting remain to be determined. We analyzed data of the multicenter German Cypher Stent Registry. From April 2002 to March 2003, 1,726 patients at 93 hospitals who received >/=1 sirolimus-eluting coronary stent were included. Median follow-up was 6.7 months. During follow-up, death occurred in 1.2% of patients (20 of 1,726), nonfatal myocardial infarction in 2.5% (43 of 1,706), and nonfatal stroke in 0.5% (7 of 1,469). TVR was performed in 8.6% of patients, with percutaneous coronary intervention in 7.3% and coronary artery bypass grafting in 1.5%. The overall rate of MACCEs or TVR was 10.8% (186 of 1,726). Independent predictors of TVR were the target vessel being a bypass graft (odds ratio [OR] 2.43, 95% confidence interval [CI] 1.41 to 4.18, p = 0.001), management of >1 lesion during the same intervention (OR 1.75, 95% CI 1.04 to 2.96, p = 0.035), 2- or 3-vessel disease (OR 1.69, 95% CI 1.05 to 2.72, p = 0.030), and age (per decade; OR 0.82, 95% CI 0.69 to 0.98, p = 0.025). These data confirm the safety and effectiveness of using the sirolimus-eluting stent in daily clinical practice. The management of bypass grafts and multiple lesions in 1 session and the presence of multivessel disease were predictors of MACCEs or TVR.
authors.affiliation: Herzzentrum, Kardiologie, Ludwigshafen, Germany. erzahn@aol.com
authors.forename: Ralf
authors.initials: R
authors.lastname: Zahn
authors.forename: Christian W
authors.initials: CW
authors.lastname: Hamm
authors.forename: Steffen
authors.initials: S
authors.lastname: Schneider
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
authors.forename: Christoph A
authors.initials: CA
authors.lastname: Nienaber
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
authors.forename: Malte
authors.initials: M
authors.lastname: Kelm
authors.forename: Benny
authors.initials: B
authors.lastname: Levenson
authors.forename: Tassilo
authors.initials: T
authors.lastname: Bonzel
authors.forename: Ulrich
authors.initials: U
authors.lastname: Tebbe
authors.forename: Georg
authors.initials: G
authors.lastname: Sabin
authors.forename: Jochen
authors.initials: J
authors.lastname: Senges
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001026:Coronary Artery Bypass; D023903:Coronary Restenosis / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D011446:Prospective Studies; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D020521:Stroke / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D020123:Sirolimus